

Financial news for ALNY dated on 2020-06-07: Alnylam Say Lumasiran Met Primary Efficacy Endpoint of 24-hour Urinary Oxalate Reduction from Month 3 to 6 Relative to Placebo, All Tested Secondary Endpoints

Financial news for ALNY dated on 2020-05-28: UBS Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to \$122

Financial news for ALNY dated on 2020-05-26: Alnylam Announces FDA Has Granted Priority Review Of Lumasiran New Drug Application For Primary Hyperoxaluria Type 1

Financial news for ALNY dated on 2020-05-15: Hedge Fund Duquesne 13F Shows Increased Stakes In Facebook, Alibaba, Netflix, Amazon, Google, Alnylman

Financial news for ALNY dated on 2020-05-13: RBC Capital Initiates Coverage On Alnylam Pharmaceuticals with Sector Perform Rating, Announces Price Target of \$150

Financial news for ALNY dated on 2020-05-07: BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to \$171

Financial news for ALNY dated on 2020-05-07: Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to \$156

Financial news for ALNY dated on 2020-05-07: Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to \$162

Financial news for ALNY dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500

Financial news for ALNY dated on 2020-05-07: Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to \$162

Financial news for ALNY dated on 2020-05-07: JP Morgan Downgrades Alnylam Pharmaceuticals to Neutral, Raises Price Target of \$137

Financial news for ALNY dated on 2020-05-06: Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target of \$160

Financial news for ALNY dated on 2020-05-06: Alnylam Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for ALNY dated on 2020-05-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ALNY dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for ALNY dated on 2020-05-06: Alnylam Cuts FY20 ONPATRO Sales Guidance From \$285M-\$315M To \$270M-\$300M

Financial news for ALNY dated on 2020-05-06: Alnylam Pharmaceuticals Q1 Adj. EPS \$(1.520) Beats \$(1.890) Estimate, Sales \$99.476M Beat \$91.560M Estimate

Financial news for ALNY dated on 2020-05-04: Vir And Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 For Treatment Of Coronavirus COVID-19

Financial news for ALNY dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for ALNY dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for ALNY dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for ALNY dated on 2020-04-22: The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership

Financial news for ALNY dated on 2020-04-21: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ALNY dated on 2020-04-20: Stocks That Hit 52-Week Highs On Monday

Financial news for ALNY dated on 2020-04-16: The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant

Financial news for ALNY dated on 2020-04-15: The Daily Biotech Pulse: Applied DNA

Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US

Financial news for ALNY dated on 2020-04-14: Nomura Maintains Reduce on Alnylam Pharmaceuticals, Lowers Price Target to \$74

Financial news for ALNY dated on 2020-04-14: Alnylam Receives Fast Track Designation For Vutrisiran For The Treatment Of The Polyneuropathy Of hATTR Amyloidosis

Financial news for ALNY dated on 2020-04-13: Blackstone And Alnylam Enter Into \$2B Strategic Financing Collaboration To 'Accelerate the Advancement of RNAi Therapeutics'

Financial news for ALNY dated on 2020-04-13: Alnylam Pharmaceuticals shares are trading higher following an announcement that Blackstone invested \$2B into the company.

Financial news for ALNY dated on 2020-04-13: Blackstone Invests \$2B in Alnylam Pharma, According to the Wall Street Journal

Financial news for ALNY dated on 2020-04-12: The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates

Financial news for ALNY dated on 2020-04-07: Alnylam Completes Rolling Submission Of New Drug Application To The FDA And Submits Marketing Authorization Application To The European Medicines Agency For Lumasiran For The Treatment Of Primary Hyperoxaluria Type 1

Financial news for ALNY dated on 2020-04-06: Alnylam and Dicerna Form a RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Financial news for ALNY dated on 2020-04-02: The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation

Financial news for ALNY dated on 2020-04-02: Vir Biotech, Alnylam Pharma To Expand Multi-Target Existing Collaboration For Development, Commercialization Of RNAi Therapeutics, Including Coronavirus Infection

Financial news for ALNY dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for ALNY dated on 2020-03-25: Alnylam Pharmaceuticals And Gen Sign Distribution Agreement In Turkey For ONPATPRO 'Gene-Silencing' RNAi Therapeutic

Financial news for ALNY dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.

Financial news for ALNY dated on 2020-03-19: Berenberg Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces \$200 Price Target

Financial news for ALNY dated on 2020-03-04: Vir Biotech, Alnylam Stitch COVID-19 Therapy Partnership

Financial news for ALNY dated on 2020-03-04: Benzinga Pro's Top 5 Stocks To Watch For Wed., Mar. 4, 2020: JWN, VIR, CMG, AHPI, GNMK

Financial news for ALNY dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for ALNY dated on 2020-03-04: Vir and Alnylam Expand Collaboration To Advance RNAi Therapeutics For The Treatment Of Coronavirus Infection, Including COVID-19

Financial news for ALNY dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for ALNY dated on 2020-02-26: Alnylam Pharma Reports ONPATPRO Approved In Brazil For Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy

Financial news for ALNY dated on 2020-02-18: Alnylam Completes Enrollment Of HELIOS-A Phase 3 Study Of Vutrisiran For The Treatment Of hATTR Amyloidosis With Polyneuropathy

Financial news for ALNY dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution

Medicines IPO

Financial news for ALNY dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for ALNY dated on 2020-02-11: Nomura Maintains Reduce on Alnylam Pharmaceuticals, Raises Price Target to \$75

Financial news for ALNY dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for ALNY dated on 2020-02-10: Stocks That Hit 52-Week Highs On Monday

Financial news for ALNY dated on 2020-02-07: Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to \$148

Financial news for ALNY dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for ALNY dated on 2020-02-06: Stocks That Hit 52-Week Highs On Thursday

Financial news for ALNY dated on 2020-02-06: Alnylam Sees FY20 ONPATTRO Net Product Revenues \$285M-\$315M

Financial news for ALNY dated on 2020-02-06: Alnylam Pharmaceuticals Q4 EPS \$(1.98) Beats \$(2.23) Estimate, Sales \$71.681M Miss \$72M Estimate

Financial news for ALNY dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for ALNY dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for ALNY dated on 2020-01-31: Alnylam Reports Receives Positive CHMP Opinion For GIVLAARI For Acute Hepatic Porphyria In Adults, Adolescents

Financial news for ALNY dated on 2020-01-12: Alnylam Preliminary FY Global Net Product Revenue \$166M vs \$220.54M Est; Q4 Revenue \$56M vs \$71.48M Est

Financial news for ALNY dated on 2020-01-10: Alnylam Initiates Rolling Submission of New Drug Application To FDA For Lumasiran For Treatment Of Primary Hyperoxaluria Type 1

Financial news for ALNY dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for ALNY dated on 2019-12-24: 10 Biotech M&A Targets Under The Scanner For 2020

Financial news for ALNY dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for ALNY dated on 2019-12-19: Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to \$190

Financial news for ALNY dated on 2019-12-18: 10 Biggest Price Target Changes For Wednesday

Financial news for ALNY dated on 2019-12-18: Cantor Fitzgerald Reiterates Overweight on Alnylam Pharmaceuticals, Raises Price Target to \$176

Financial news for ALNY dated on 2019-12-17: Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to \$150

Financial news for ALNY dated on 2019-12-17: Alnylam Announces ILLUMINATE-A Phase 3 Study Of Lumasiran Met Primary And All Tested Secondary Endpoints

Financial news for ALNY dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for ALNY dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for ALNY dated on 2019-12-04: The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for ALNY dated on 2019-11-27: Stocks That Hit 52-Week Highs On

Wednesday

Financial news for ALNY dated on 2019-11-27: The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

Financial news for ALNY dated on 2019-11-26: Alnylam Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.

Financial news for ALNY dated on 2019-11-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ALNY dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for ALNY dated on 2019-11-25: BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to \$143

Financial news for ALNY dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for ALNY dated on 2019-11-25: 36 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ALNY dated on 2019-11-24: The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More

Financial news for ALNY dated on 2019-11-22: Stocks That Hit 52-Week Highs On Friday

Financial news for ALNY dated on 2019-11-22: The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

Financial news for ALNY dated on 2019-11-22: UPDATE: Alnylam Reports Initiation Of HELIOS-B Phase 3 Study; Offers Initial Clinical Results With ALN-AAT02, ALN-HB02

Financial news for ALNY dated on 2019-11-22: Alnylam Offers 2020 Product, Pipeline Goals

Financial news for ALNY dated on 2019-11-21: BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to \$138

Financial news for ALNY dated on 2019-11-21: Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to \$141

Financial news for ALNY dated on 2019-11-21: UPDATE: Cantor Says Is Looking Forward To Added Color At Alnylam's R&D Day Friday, Continues To Believe Co. Could Be \$15B-\$20B Co. Over Next 12-18 Months

Financial news for ALNY dated on 2019-11-21: Cantor Believes Alnylam Is In 'Breakout Mode,' Sees Recent Strength From 2 Factors: 1. Greater Confidence That RNAi Is A Real New Class Of Commercial Medicines, 2. Less Concern Pfizer's Tafamidis Will Take Meaningful Share From Onpattro Launch

Financial news for ALNY dated on 2019-11-21: 10 Biggest Price Target Changes For Thursday

Financial news for ALNY dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Collectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for ALNY dated on 2019-11-21: Cantor Fitzgerald Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to \$159

Financial news for ALNY dated on 2019-11-21: Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to \$131

Financial news for ALNY dated on 2019-11-21: 63 Biggest Movers From Yesterday

Financial news for ALNY dated on 2019-11-20: Alnylam Pharma Shares Resume Trade, Pullback From Session High, Still Up 7.3% For Session

Financial news for ALNY dated on 2019-11-20: Alnylam Pharma Shares To Resume Trade At 3:30 p.m. EST

Financial news for ALNY dated on 2019-11-20: Alnylam Pharmaceuticals Inc Prices Genetic Disorder Treatment Givlaari At \$575K/Yr

Financial news for ALNY dated on 2019-11-20: Ironwood Pharmaceuticals Shares Up 2.78% For The Session; NOTE: Co. Previously Entered Gastrointestinal Disease Education And Promotional Agreement With Alnylam Pharmaceuticals For Givlaari, Which Today Received FDA Approval

Financial news for ALNY dated on 2019-11-20: FDA PR Confirms Approval Of Alnylam's Givlaari For Treatment Of Adult Patients With Acute Hepatic Porphyria

Financial news for ALNY dated on 2019-11-20: FDA Granted Approval To Alnylam's Givlaari For Treatment Of Adult Patients With Acute Hepatic Porphyria

Financial news for ALNY dated on 2019-11-20: Alnylam Pharmaceuticals Shares Halted, News Pending

Financial news for ALNY dated on 2019-11-20: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ALNY dated on 2019-11-20: Benzinga's Top Upgrades, Downgrades For November 20, 2019

Financial news for ALNY dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for ALNY dated on 2019-11-20: Oppenheimer Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces \$128 Price Target

Financial news for ALNY dated on 2019-11-19: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ALNY dated on 2019-11-17: The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

Financial news for ALNY dated on 2019-11-13: Bank of America Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces \$110 Price Target

Financial news for ALNY dated on 2019-11-10: The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict

Financial news for ALNY dated on 2019-10-31: Alnylam Pharmaceuticals Q3 EPS \$(1.5) Up From \$(1.56) YoY, Sales \$70.061M Up From \$2.069M YoY

Financial news for ALNY dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for ALNY dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for ALNY dated on 2019-10-10: Alnylam Reports Filing For Marketing Authorization Of ONPATTRO For Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy In Brazil

Financial news for ALNY dated on 2019-09-27: Alnylam Pharmaceuticals Option Alert: Dec 20 \$85 Calls at the Ask: 1000 @ \$5.201 vs 55 OI; Earnings 11/6 Before Open [est] Ref=\$80.8

Financial news for ALNY dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for ALNY dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for ALNY dated on 2019-09-16: Alnylam Pharma Reports Initiated APOLLO-B Phase 3 Study Of Patisiran For Treatment Of Transthyretin Amyloidosis With Cardiomyopathy

Financial news for ALNY dated on 2019-09-13: Alnylam Pharma Presents New Evidence Showing Significant Association Of V122I With Clinical Diagnosis Of Polyneuropathy

Financial news for ALNY dated on 2019-09-04: UBS Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to \$96

Financial news for ALNY dated on 2019-09-03: Cantor Fitzgerald On Alnylam Pharmaceuticals Also Notes 'If the ORION-9 and ORION-10 readouts expected this month also look clean, we think that overall ALNY shares may move 10-20% cumulatively based on these updates

Financial news for ALNY dated on 2019-09-03: Cantor Fitzgerald Reiterates Overweight, \$138 Tgt On Alnylam Pharma As Firm Notes Co's Partner Medicines Co. Presented ORION-11 Ph3 Data For Inclisiran And Firm Thinks 'the detailed ORION-11 data is supportive of ALNY platform efficacy and safety'

Financial news for ALNY dated on 2019-09-03: Piper Jaffray Maintains Overweight on

Alnylam Pharmaceuticals, Raises Price Target to \$145

Financial news for ALNY dated on 2019-09-02: The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight

Financial news for ALNY dated on 2019-08-29: The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings

Financial news for ALNY dated on 2019-08-20: Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

Financial news for ALNY dated on 2019-08-13: Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter US GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Financial news for ALNY dated on 2019-08-07: Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to \$124

Financial news for ALNY dated on 2019-08-06: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for ALNY dated on 2019-08-06: Alnylam Pharmaceuticals Q2 Adj. EPS \$(1.83) Beats \$(1.86) Estimate, Sales \$44.714M Miss \$69.2M Estimate

Financial news for ALNY dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for ALNY dated on 2019-08-05: Alnylam Phamra Reports FDA Granted Priority Review Of Givosiran New Drug Application For Treatment Of Acute Hepatic Porphyria; PDUFA Date Set For Feb. 4, 2020

Financial news for ALNY dated on 2019-07-23: Alnylam Launches ONPATTRO For The Treatment Of Polyneuropathy In hATTR Amyloidosis RNAi Therapeutic

Financial news for ALNY dated on 2019-07-16: Alnylam And 23andMe Collaborate On +MyFamily Program To Increase Awareness Of TTR-Related Hereditary Amyloidosis

Financial news for ALNY dated on 2019-07-11: Alnylam Pharma CFO Manmeet Soni To Resign; Jeff Poulton Named Replacement

Financial news for ALNY dated on 2019-07-03: The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief

Financial news for ALNY dated on 2019-07-01: Alnylam Submits a Marketing Authorization Application to the European Medicines Agency for Givosiran for the Treatment of Acute Hepatic Porphyria

Financial news for ALNY dated on 2019-06-24: Alnylam Presents New ONPATTRO Results at the 2019 Peripheral Nerve Society Annual Meeting

Financial news for ALNY dated on 2019-06-21: Alnylam Announces Progress With RNAi Therapeutics Platform, Including Oral Route Of Administration And CNS And Ocular Delivery

Financial news for ALNY dated on 2019-06-18: Alnylam Reports Japanese Approval Of ONPATTRO For Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy

Financial news for ALNY dated on 2019-06-17: Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1

Financial news for ALNY dated on 2019-06-13: Alnylam Pharma To Report New Clinical Results for ONPATTRO(r) (patisirán) at Peripheral Nerve Society Annual Meeting, Congress of the European Academy of Neurology

Financial news for ALNY dated on 2019-06-05: Alnylam Completes Rolling Submission Of New Drug Application To FDA For Givosiran For The Treatment Of Acute Hepatic Porphyria

Financial news for ALNY dated on 2019-05-31: Alnylam Pharma Reports Dosing Of First Patient in Phase 1 Study of ALN-AGT

Financial news for ALNY dated on 2019-05-29: 5 Small-Cap Biotechs In Citi's Buy List With Big Upside Potential

Financial news for ALNY dated on 2019-05-23: Goldman Sachs Assumes Alnylam Pharmaceuticals, Inc. - Common Stock at Neutral, Announces Price Target \$80

Financial news for ALNY dated on 2019-05-03: Alnylam Offering By Sanofi Priced At \$80.25/Share

Financial news for ALNY dated on 2019-05-02: BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Inc. - Common Stock, Raises Price Target to \$128

Financial news for ALNY dated on 2019-05-01: Alnylam Pharmaceuticals Q1 EPS \$(1.73) Beats \$(2.07) Estimate, Sales \$33.294M Beat \$23.65M Estimate

Financial news for ALNY dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for ALNY dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for ALNY dated on 2019-04-15: Stifel Nicolaus Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to \$116

Financial news for ALNY dated on 2019-04-15: Cantor Fitzgerald Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to \$138

Financial news for ALNY dated on 2019-04-15: BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to \$126

Financial news for ALNY dated on 2019-04-15: Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

Financial news for ALNY dated on 2019-04-12: Evercore ISI Group Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces \$120 Price Target

Financial news for ALNY dated on 2019-04-09: SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to \$70

Financial news for ALNY dated on 2019-04-09: BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to \$119

Financial news for ALNY dated on 2019-04-08: Regeneron, Alnylam Strike \$1B Collaboration For RNAi-based Therapeutics

Financial news for ALNY dated on 2019-04-08: Alnylam Pharma Shares Resume Trade, Up 0.9%

Financial news for ALNY dated on 2019-04-08: Alnylam Pharma Shares To Resume Trade At 7:30 a.m. EDT

Financial news for ALNY dated on 2019-04-08: UPDATE: Alnylam Will Be Eligible For Added \$200M In Potential Near-Term Milestones

Financial news for ALNY dated on 2019-04-08: UPDATE: Regeneron Will Invest \$800M In Alnylam Through Upfront Cash, Equity Investment

Financial news for ALNY dated on 2019-04-08: Alnylam, Regeneron Report Collaboration To Discover, Develop, Commercialize RNAi Therapeutics Focused On Ocular, Central Nervous System Diseases

Financial news for ALNY dated on 2019-04-08: Alnylam Pharm Shares Halted News Pending

Financial news for ALNY dated on 2019-04-08: Alnylam, Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration

Financial news for ALNY dated on 2019-04-03: Jim Cramer Shares His Thoughts On Mastercard, US Steel And More

Financial news for ALNY dated on 2019-03-07: 58 Biggest Movers From Yesterday

Financial news for ALNY dated on 2019-03-06: Hearing Evercore ISI Upgraded Alnylam From In Line To Outperform

Financial news for ALNY dated on 2019-03-06: 45 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ALNY dated on 2019-03-06: UPDATE: Alnylam Reports Some Patients Showed Serious Adverse Events

Financial news for ALNY dated on 2019-03-06: Alnylam Pharmaceuticals shares are

trading lower after the company announced that four of its secondary endpoints did not meet the hierarchical threshold for significance in a Phase 3 study of givosiran; many patients also reported serious adverse events.

Financial news for ALNY dated on 2019-03-06: UPDATE: Alnylam Says Four Of Its Secondary Endpoints Did Not Meet The Hierarchical Threshold For Significance

Financial news for ALNY dated on 2019-03-06: Alnylam Pharmaceuticals Shares To Resume Trade At 7:30 a.m.

Financial news for ALNY dated on 2019-03-06: Alnylam Reports Positive ENVISION Phase 3 Study Of Givosiran In Acute Hepatic Porphyria Met Primary And Majority Of Secondary Endpoints

Financial news for ALNY dated on 2019-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2019

Financial news for ALNY dated on 2019-03-05: Morgan Stanley Upgrades Alnylam Pharmaceuticals to Overweight

Financial news for ALNY dated on 2019-02-08: The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

Financial news for ALNY dated on 2019-02-06: UPDATE: Alnylam Sees Topline Phase 3 Readout Data Early 2019

Financial news for ALNY dated on 2019-02-06: Alnylam Highlights Publication Of Phase 1 Givosiran In New England Journal Of Medicine

Financial news for ALNY dated on 2019-01-29: 50 Biggest Movers From Yesterday

Financial news for ALNY dated on 2019-01-28: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for ALNY dated on 2019-01-23: UBS Initiates Coverage On Alnylam Pharmaceuticals with Neutral Rating

Financial news for ALNY dated on 2019-01-23: Alnylam Pharma to Collaborate with CAMP4 Therapeutics to Research Rare Diseases

Financial news for ALNY dated on 2019-01-15: Alnylam Pharma shares are trading lower after the company priced 5M share stock offering at \$77.50/share.

Financial news for ALNY dated on 2019-01-15: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ALNY dated on 2019-01-15: Alnylam Pharmaceuticals Prices 5M Share Public Offering of Common Stock @\$77.50/Share

Financial news for ALNY dated on 2019-01-14: Alnylam Pharmaceuticals shares are trading lower after the company announced proposed public offering of 5 million shares of common stock.

Financial news for ALNY dated on 2019-01-14: Alnylam Pharma Reports Offer Of 5M Shares Of Common Stock

Financial news for ALNY dated on 2019-01-11: UPDATE: Guggenheim Reiterates Alnylam Pharmaceuticals As Top Pick As Firm Continues 'to think the Onpattro launch will go well given the existing pool of identified patients and Onpattro's profile vs. competitors'; Reiterates Buy, \$105 Target